Shire is teaming up with biotechnology firm ArmaGen Technologies in order to develop an investigational enzyme replacement therapy (ERT) for the treatment of Hunter syndrome.
Under the agreement, Shire will hold worldwide commercialization rights to ArmaGen's compound AGT-182. In return the Calabasas, California-based biotech will...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
